James Driscoll, MD, PhD
The Driscoll Lab focuses its research on increased understanding of the biology of plasma cells under physiologic and pathologic conditions as a means to improve human health. Over the past decade, they focused their laboratory and clinical research studies on the plasma cell malignancy multiple myeloma (MM).
Jordan Winter, MD
The Winter lab studies basic, translational, and clinical aspects of pancreatic cancer with a principal goal to discover new and effective therapies. We seek to understand how pancreatic cancers develop resistance to standard chemotherapies. Additionally, we are interested in understanding how pancreatic cancer is able to successfully adapt to the extremely harsh metabolic conditions that are present throughout the tumor microenvironment such as hypoxia and low nutrient levels.
- Ear, Nose & Throat
Martin L. Basch, PhD
The Basch Lab uses mouse embryo as a model system to understand how the inner ear forms. The lab studies how the different cell types in the cochlea interact with each other during embryonic development. The lab goal is to apply the lessons learned from normal development towards regenerative therapies in cases of congenital deafness and age-related hearing loss.
- Harrington Discovery Institute
Atul Chopra, MD PhD
The Chopra lab focuses its research in the field of energy homeostasis and metabolic disease. Through the assessment of humans with genetic defects in the processing of energy, the lab works to identify new genes and pathways that have escaped attention so far. Its goal is to identify novel processes and paradigms within the realm of energy homeostasis using human and mouse genetics as well as cutting edge molecular biology.
Seth Field, MD
The goal of the Field lab is to use discoveries in fundamental biology to fuel the development of new approaches to treat human disease and provide insight into the mysterious organelle, the Golgi.
Mukesh K. Jain, MD
The Jain laboratory identified KLFs as nodal regulators of cardiovascular biology and metabolism. Mukesh K. Jain, MD translated this work and established KLFs as key targets of pharmacologic agents.
Andrew Pieper, MD
The Pieper lab strives to identify and pursue important biological insights into neuropsychiatry, with particular focus on neurodegeneration in disease, injury, and normal aging. The ultimate goal is to improve human brain health through translational basic science leading to new therapies for patients suffering from currently incurable or difficult to treat neuropsychiatric disorders.
Jonathan Stamler, MD
The Stamler lab pioneered the field of S-nitrosylation-mediated protein control, a fundamental mechanism of cellular regulation and signaling that operates across phylogeny and cell type. It is currently developing first in-class agents that modulate S-nitrosylation in a tissue and target-specific manner, promising new treatments for human disease.
Irina Pikuleva, PhD
Vice Chair of Research
Carl F. Asseff, M.D. Professor of Ophthalmology
Director of the Visual Sciences Research Center
Case Western Reserve University
Shigemi Matsuyama, DVM, PhD
Ophthalmology and Visual Science (Primary)
Hematology and Oncology, Department of Medicine
Department of Pathology
Department of Pharmacology
General Medical Science
Case Western Reserve University
Case Comprehensive Cancer Center
Robert Salomon, PhD
Mabery Professor of Chemistry and Ophthalmology, Case Western Reserve University
- Pediatric Labs
Pediatric Cardiology and Cardiothoracic Surgery
The Devaney lab maintains an active bench-to-bedside research program which includes both basic science and clinical research. At the bench, the lab is focused on the genetic modification of muscle motor proteins in normal and failing hearts. Additionally, the lab is engineering autologous tissue for the treatment of congenital heart disease. At the clinic, Dr. Eric Devaney's research involves the applications of ventricular assist devices in pediatric heart failure as well as clinical outcomes in pediatric heart surgery.
The Jenkins lab develops and applies novel biomedical optics tools and techniques for investigating congenital heart disease and diseases of the peripheral nervous system. The primary optical tools are infrared control of excitable tissues (optical pacing, infrared neuromodulation), optical coherence tomography (OCT), and microscopy (light-sheet microscopy, optical mapping).
- Urology Labs
The James and Eillen Dicke Urology Research Laboratory
Sanjay Gupta, PhD
Professor & Endowed Chair, Department of Urology, School of Medicine
Dr. Sanjay Gupta’s research involves basic, translational and clinical areas of focus. He has made ground-breaking contributions to the fields of cancer biology, epigenetics and pharmacology, in particular, identification of biomarkers and targets, development of prognostic models and application of small molecules for prevention and therapy of cancer. His recent interest is on development of new technologies based on artificial intelligence and bio-printing based cancer model systems.
Magdalena M. Grabowska, PhD
Assistant Professor, Department of Urology, Case Western Reserve University
The Grabowska Lab focuses on genitourinary conditions like prostate cancer, benign prostatic hyperplasia, and bladder cancer. The team of researchers uses patient tissues, pre-clinical models, and cell lines to understand how these conditions develop and acquire therapeutic resistance to standard therapies. We collaborate with clinical, basic, and translational researchers to create an interdisciplinary research program to better understand these diseases with the goal of improving patient outcomes.
Adonis Hijaz, MD
Vice Chair Academic & Research, Urology Institute
Dr. Adonis Hijaz is the Lester Persky Professor of Urology at CWRU and is a specialist in female pelvic medicine and reconstructive surgery. Over the last 15 years, he has conducted clinical, basic science and translational research on the topic of urinary incontinence. The focus of the his research Laboratory at CWRU has been on the study of the mechanisms and pathophysiology of stress urinary incontinence (SUI) with focus on the role of mesenchymal stem cells (MSCs) in the treatment of SUI. Research conducted in his laboratory has also investigated the role of stem cell homing chemokines in the treatment of SUI. Dr. Hijaz’s laboratory has specific strength in development of small animal models of urinary incontinence with an emphasis on models that investigate mechanisms of childbirth injury to the urethral continence mechanism. The goal of this research to harness the knowledge of mechanisms of recovery in the development of pathophysiologically-based treatment alternatives that emphasizes early intervention. In addition to the former field of research, the laboratory has collaboration with departments of biomedical engineering and Mechanical and Aerospace Engineering. The collaboration has focused on innovative solutions for pelvic floor and incontinence repair with next generation biodegradable biotextile material. This collaboration has received funding from local, state and federal sources to validate and further develop the technology. In the most recent years, the team has been investigating he role of immune-regenerative macrophages in the treatment SUI. The laboratory has been supported by NIH and by the Lester Persky Endowment.
Jonathan Shoag, MD
In an effort to develop precision tools for cancer care, Jonathan Shoag, MD conducts translational and clinical research focused on bringing large data, genomic sequencing and novel AI and statistical techniques for better patient outcomes. More specifically, Dr. Shoag’s objective is to identify drugs that have activity against the normal prostate and can be used to understand and treat prostate cancer. The Damon Runyon Cancer Research Foundation supports Dr. Shoag’s novel approaches to apply novel statistical and machine learning approaches on large scale clinical data to discover new therapies and pathways important in prostate cancer. He will then test these therapies in genetically engineered and patient-derived prostate cancer models. Identifying active drugs against prostate cancer that are already FDA-approved or have been previously studied in clinical trials for other cancers can aid in understanding prostate cancer biology and can rapidly benefit patients with advanced disease.